---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008249"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T12:51:28.238847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB

## Summary
- Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.
- Net loss $16.3M for FY2024 vs $2.2M in 2023 (2023 included noncash gain).
- Positive 16-week extension results: improvement on CDR-SB (p<0.001 vs old capsules; p=0.003 vs placebo).
- Plan to initiate Phase 3 trial in mid-2026 after regulatory meetings.
- Added senior VPs Claudia Ordonez (Medical Science) and Mark De Rosch (Regulatory).

## SEC filing metadata
- accession: 0001437749-25-008249
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/0001437749-25-008249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/crvo20250318_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008249
- JSON: https://secwatch.observer/filing/0001437749-25-008249.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.